GENETIC TECHNOLOGIES ADR REP 3 (GENE)

310 posts / 0 new
Letzter Beitrag
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
GENETIC TECHNOLOGIES ADR REP 3 (GENE)

Kennt hier jemand die Aktie? ich habe hier nichts drüber gefunden.


Company description
Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services. The Company's cancer diagnostics business focused on building a sustainable stable of products and services. The Company operates in three divisions: genetic testing, including cancer diagnostics; licensing, and research. BREVAGen provides a personalized genetics based risk score for such women, so guiding preventive therapy or advanced monitoring decisions. The majority of its customers are clinicians. The Company's five overseas subsidiaries include Gtech International Resources Limited, Genetic Technologies (Beijing) Limited, GeneType AG, GeneType Corporation and Phenogen Sciences Inc. In April 2010, Genetic Technologies acquired the assets of Perlegen Sciences Inc., which included non-familial breast cancer risk assessment test BREVAGen.


http://www.gtglabs.com


Der Titel könnte interessant werden.


Last $ 3.56


News:


http://www.gtglabs.com.au/announcements/genetic-technologies-executes-covenant-not-to-sue-and-release-agreement-with-one-lambda-inc


Bisher:


http://www.gtglabs.com.au/images/stories/GENE_1H12_Earnings_Preview.pdf


(Info vom Trader-Forum) 


Gruss,


Simona


 

AnhangGröße
Image icon gene.gif10.42 KB
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Infos
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Info von heute

für Interessierte:


Einige Finanzberichte sowie Jahresbericht Ende Juni 2012 und Quartalsbericht Ende September 2012:


http://www.gtgcorporate.com/investor-centre/company-reports


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Da bröckelt der Kurs seit Tagen, ohne spezielle Meldung, steht momentan um $ 2.02. Es wäre mal wieder eine Erfolgsnachricht fällig. Wo bleibt sie? Wann sieht man da wieder Kurse um 5.-?


Gruss,


Simona


PS:


Da kommt noch was:


17:32:28
28-11-2012 15:22  WSJ BLOG/MarketBeat: Stocks to Watch: Knight Capital Group, Green Mountain, Fresh Market


U.S.-listed shares of Australian genetic-testing company Genetic Technologies Ltd. (GENE) plunged 20% to $1.99 premarket following the resignations of two directors from its board, as well as the immediate resignation of Chief Executive Paul MacLeman announced in a filing with the U.S. Securities and Exchange Commission after the company's annual general meeting. 



 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Da schaue ich morgen mal genauer hin. Heute war ich zu spät. Offenbar brauchen sie eine neue Führungs-Crew. Die ist vermutlich bereits servierbereit. Sowas macht man ja nicht echt einfach so kurzfristig. Ist offenbar so eine Art australische 'Roche', nicht wegen der Führung, wegen der Pharma. Biggrin Dirol

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Ja genau Biggrin


29.11.2012 | 11:31
 


MarketWire · Genetic Technologies Provides Update on Board and Management Changes
MELBOURNE, AUSTRALIA -- (Marketwire) -- 11/29/12 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the appointment of Dr. Mal Brandon to the position of Chairman. In addition, Ms. Alison Mew, the Company's Chief Operating Officer will now serve as Acting Chief Executive Officer and Mr. Tom Howitt will continue in his role as Chief Financial Officer. These appointments follow the departure of Directors, Dr. Mel Bridges, Mr. Huw Jones and Mr. Greg Brown along with Dr. Paul MacLeman, Chief Executive Officer.


"On behalf of the Board and management team, I wish to extend our gratitude to the departing Directors for their service and, in particular, to Paul MacLeman who was integral in transforming Genetic Technologies into a commercial stage women's health company. Moving forward, the strategy for corporate growth remains unchanged as we continue to ramp-up BREVAGen™ sales and our overall U.S. operations while driving the Company's successful global licensing program," commented Dr. Mal Brandon, Chairman of Genetic Technologies.


The departure of the aforementioned Directors and Chief Executive Officer was announced on November 27th as part of the Company's Annual General Meeting results held on November 26th in Melbourne, Australia.


About BREVAGen™
The BREVAGen™ breast cancer risk stratification test is a novel genetic test panel that examines a patient's DNA to detect the absence or presence of certain common genetic variations (SNPs) associated with an increased risk for developing breast cancer. The test is designed to help physicians assess aggregate breast cancer risk from these genetic markers, plus factors from a standard clinical assessment based on a patient's family and personal history, thus giving a clearer picture of an individual woman's risk of developing breast cancer. The BREVAGen™ test may be especially useful for women predisposed to hormone dependant breast cancer, including those who have undergone breast biopsies, as the test will provide information that can help physicians recommend alternative courses of action, such as more vigilant, targeted surveillance or preventive therapy, on a personalized patient-by-patient basis. For more information, please visit http://www.brevagen.com, or http://www.brevagen.com.au


Gruss,


Simona

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 02.03.2017
Mitglied seit: 16.04.2010
Kommentare: 1'285

Die kommen mir irgendwie bekannt vor. Was da nicht vor längerer Zeit mal drüber geschrieben worden, aber nicht als eigener Thread sondern bei Pharma-Titeln allgemein? GENE sagt mir was, ich glaube mich zu erinnern, dass die schon recht erfolgreich waren bezüglich Zulassungen.

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Ja schon, aber das war seinerzeit unter 'Hot Stocks', weiss nicht mehr, von wem. Ist schon lang her. Ich hatte damals auch etwas davon, sozusagen als stiller Mitflieger. Die Beiträge darüber finde ich auch nicht mehr. Aber auf dem Kursniveau könnte man ja schon mal wieder.........

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Ja das war's, Pleasantry da waren wir doch zusammen kurz drin. Das war noch im 'alten' Forum, müsste ca. anfangs 2011 gewesen sein? Darum findet man vermutlich keine Beiträge mehr darüber. Jetzt kann man da aber nicht rein, soviel ich sehe. Das Volumen ist nicht da. Sollte man ändern. Ich kam gestern noch rein mit einem Nachkauf.


Gruss,


Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Wirklich schade, dass es da kein Volumen gibt. Sonst könnte man schon was machen. Vielleicht kommt das ja noch. Ich schaue gelegentlich hin.

Emil

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Tatsächlich, endlich, es tut sich was.............:biggrin:

Emil

Lorenz
Bild des Benutzers Lorenz
Offline
Zuletzt online: 02.03.2017
Mitglied seit: 16.04.2010
Kommentare: 1'285

Jetzt ist der gesuchte Thread grad ganz nahe dank Vagnum. :airkiss:

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Info

Ja, danke.


News gibt es auch gleich:


Wink


ASX ANNOUNCEMENT
December 6, 2012


Genetic Technologies resolves its patent infringement claim against
454 Life Sciences Corporation



In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Limited (ASX: GTG;
NASDAQ: GENE) is pleased to report it has executed a Settlement, Covenant and License Agreement
with 454 Life Sciences Corporation (“454”) of Branford, Connecticut, USA, which includes 454, its
affiliates and companies related to Roche Holding Ltd.
The precise commercial terms of the Agreement are covered by formal confidentiality provisions and
cannot be disclosed. This Agreement was achieved further to GTG’s continuing patent assertion program
in the US and other jurisdictions.
454 was a counterparty to the third formal patent assertion suit filed by Genetic Technologies against ten
companies in the US District Court for the District of Colorado (see GTG announcement dated May 26,
2011) and is now the fifth counterparty from that case to reach resolution with Genetic Technologies.
Discussions with other parties are ongoing and progressing. Further details will be released to the Market
as appropriate.
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mervyn Jacobson
VP, Global Licensing and Intellectual Property
Genetic Technologies Limited
Phone: +61 419 657 915


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Info
Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Ich habe sie. Bin vorsorglich dabei. :biggrin::cool:

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Info
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Infos/News aktuell

Zum neuen Jahr heute auch gleich einige wissenswerte und wichtige Infos von GENE:

http://www.asx.com.au/asxpdf/20130107/pdf/42c9v98f7kyp7q.pdf

Gruss,

Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Da habe ich zufällig grad noch News gefunden. Ich habe da ja auch etwas liegen. Man war schon auf 2.90 heute. Wo bleibt die Nachhaltigkeit?
Weitere Berichte erwünscht.


http://www.asx.com.au/asxpdf/20130125/pdf/42clt0y35zh62m.pdf

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Nun kommt da wieder etwas Bewegung rein. Zahlentermin in Sicht?


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Halbjahreszahlen per 31.12.2012

Hier wird in die Zukunft investiert:


MELBOURNE, AUSTRALIA -- (Marketwire) -- 02/22/13 -- Genetic Technologies Limited


(ASX : GTG) (NASDAQ: GENE)



  • Increases in BREVAGen™ samples received demonstrate clear market traction



  • Encouraging early results achieved in the new molecular diagnostics reimbursement environment



  • Increased licensing revenues show renewed success from global assertion programs
     

Genetic Technologies Limited (ASX : GTG) (NASDAQ: GENE) today announced its financial results for the first half of the Company's fiscal year ending 30 June 2013. The Company reported a total comprehensive loss of $3.7 million for the period, which compares to a loss of $3.3 million for the corresponding prior period. The Company's cash position as of 31 December 2012 totalled $5.9 million.


Of particular note during the period, the Company saw a marked improvement in the number of samples received for BREVAGen™, its flagship non-familial breast cancer risk assessment test. The 2013 half-year delivered 546 samples for testing, representing an increase of nearly 240% over the corresponding prior period and more than 30% over the number received for the entire previous twelve-month period, demonstrating increasing traction in the market. Further, the Company noted a significant improvement in the number of samples received in the December quarter (368), more than double those received in the preceding September quarter (178).


The achievement of "Out of State Licensure" for the key states of Florida and California during the period was a milestone achievement, enabling access to significant new markets for the test. The Company expects to receive approval to launch the test in New York State during the fourth quarter of 2013. Once achieved, BREVAGen™ will be approved for sale in all 50 U.S. States.


1 January 2013 marked a material change in the U.S. reimbursement environment for molecular diagnostics, resulting in the removal of the CPT code stack system for insurance claims. In response, the Company has initiated strategies to maintain the positive performance of the reimbursement program achieved to date.


"We are very pleased with the increased traction for BREVAGen™ that has been demonstrated through refinements in messaging and sales channel management since the appointment of Mark Ostrowski as Senior VP Sales and Marketing in September," said Alison Mew, Chief Executive Officer of Genetic Technologies. "Mark brings to the Company a wealth of experience from his time at Myriad Genetics and he has already applied a number of important initiatives to enhance the BREVAGen™ selling process and maximize our market effectiveness. In response to recent changes made to reimbursement guidelines in the U.S., I am pleased that the initiatives we have put in place to address levels of reimbursement received and timeline of claims adjudication have delivered encouraging results thus far."


Revenues generated by the Company's global out-licensing program for the half-year under review were more than doubled those of the half-year period ended 31 December 2011, and materially exceeded the revenues generated by the program for the full 2012 financial year. Importantly, recent changes to the program have streamlined the Company's operations and established new arrangements under which the Company's share of future licensing revenues will increase. It is anticipated that this renewed momentum will continue into the second half of the current financial year resulting in additional licenses to the Company's non-coding technology being granted.


http://www.gtglabs.com/


Gruss,


Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Erstaunlich, wie die sich halten. Da wird offenbar mit dem Ausblick fest gerechnet. Das 52-Wochenhoch im Chart könnte ebenfalls locken. Ich weiss noch nicht, was ich mache damit.


 


 

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Ev. unter's Kopfkissen legen und etwas warten. Gut, wenn man die Kosten noch etwas verringern kann.


Bei den Sachen ist man ja vorzugsweise schon drin, wen sie abgehen (s. CBMX).


Gruss,


Simona

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Für Interessierte: Da gibt es auch mal wieder News:


http://www.gtglabs.com/images/stories/US_patent_re-examination_update.pdf


Gruss,


Simona


 

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Gehen ab wie die Sau, was ist los?

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Habe keine Info.


War aber schön, bisher Tageshöchst 3.28, + ca. 38,xx%.


Bin mal raus mit einem unteren Teil. Smile


 


Gruss,


Simona

Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Supermegacool. 2/3 wurden verkauft, einer bleibt bis zum nächsten Hoch, oder es gibt noch einen Zukauf. Kommt auf die News an. Vermutlich waren es die Q-Zahlen. Sieht man dann morgen.

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324
Emil
Bild des Benutzers Emil
Offline
Zuletzt online: 07.01.2017
Mitglied seit: 28.09.2007
Kommentare: 2'865

Emil

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Ja, und habe noch eine Kleinigkeit gekauft heute. Bis zum nächsten Hoch. Dirol

Simona
Bild des Benutzers Simona
Offline
Zuletzt online: 30.05.2016
Mitglied seit: 19.05.2006
Kommentare: 1'324

Info:


MELBOURNE, AUSTRALIA -- (Marketwired) -- 05/03/13 -- Genetic Technologies Limited (ASX: GTG) (NASDAQ: GENE), is pleased to advise that it has executed an agreement with Three Rivers Provider Network, Inc. of Chula Vista, California, USA.


Three Rivers Provider Network ("TRPN") claims to be the largest supplemental PPO Network Foundation in the US, providing healthcare benefits to more than 10 million members, at more than 1 million locations nationwide.


The agreement with TRPN is the fifth such credentialing agreement executed between the Company and similar U.S. Preferred Provider Organisations ("PPOs") and increases the total number of covered lives, for which its BREVAGen™ test could be adjudicated as "in-network," to more than 23 million.


The impact of this credentialing has been clearly demonstrated in reviewing reimbursement claims for the BREVAGen™ test since its launch. As reported recently by the Company in its March 2013 Quarterly Activities Report, the average reimbursement received in respect of claims that were adjudicated as "in-network," was more than 25% higher than the amounts received in respect of claims that were adjudicated as "out of network," with the time taken to collect the funds also being materially shorter.


Importance of credentialing contracts executed with Preferred Provider Organisations
As mentioned, credentialing with PPOs such as TRPN allows for expedited claim adjudication as "in-network." This provides improved cash flow via faster payment while still obtaining an acceptable level of reimbursement, and also reduces the costs incurred through appealing denials. Once BREVAGen™ sample volumes reach a significant level and Genetic Technologies has gathered any necessary clinical utility data, the Company will approach insurers directly to contract.


A PPO is a managed care organisation of medical doctors, hospitals and other health care providers who has covenanted with an insurer or a third-party administrator to provide health care at reduced rates to the insurer's or administrator's clients. Credentialing is a process whereby provider organisations such as physicians, care facilities and ancillary providers (including testing service providers such as GTG's subsidiary, Phenogen Sciences) contract directly with the PPO. Contracts with PPOs are fundamental to having claims for the BREVAGen™ test adjudicated "in-network."


Credentialing contracts have now been executed with Three Rivers Provider Network, Prime Health Services, National Preferred Provider Network / PlanCare America / Ohio Preferred Provider Network LLC (NPPN / OPPN), Galaxy Health Network and Fortified Provider Network. The Company is now actively pursuing further agreements with other PPOs in order to further extend access to an increased number of covered lives.



Gruss,
Simona

Seiten